Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

NER1006 preparation improve cleansing prior to colonoscopy

28 Jul 2020

NER1006, a 1-L polyethylene glycol (PEG)-based preparation for colonoscopy, is good for the overall cleansing of the colon, reports a recent meta-analysis.

Drawing from the databases of PubMed and Embase, researchers identified three randomized controlled trials eligible for analysis. The pooled sample included 1,879 patients who received different NER1006 dosing regimens and whose average ages ranged from 52.9–57.5 years.

The overall cleansing success rate was significantly higher in patients who had received the NER1006 as opposed to those who had received standard preparations, as assessed by the Harefield Cleansing Scale (HCS; odds ratio [OR], 1.28, 95 percent confidence interval [CI], 1.00–1.62; p=0.047). The same result was obtained when cleansing was evaluated using the Boston Bowel Preparation Scale (BBPS; OR, 1.43, 95 percent CI, 1.13–1.80; p=0.003).

Moreover, researchers reported that NER1006 compared to standard preparations resulted in better cleansing of the right colon, as determined by the HCS (OR, 2.13, 95 percent CI, 1.16–3.94; p=0.015). When assessed using the BBPS, NER1006 was only nominally better than standard preparations (OR, 1.72, 95 percent CI, 0.87–3.38; p=0.116).

The superior cleansing efficacy of NER1006 did not come with trade-offs in adenoma detection rate (ADR). Pooled analysis showed that ADR was comparable between NER1006 and standard preparations (OR, 1.03, 95 percent CI, 0.84–1.27; p=0.769). ADR in the right colon was only nominally higher (OR, 1.19, 95 percent CI, 0.73–1.92; p=0.485).

Safety signals, however, were present. NER1006 patients reported significantly more treatment-emergent adverse events (OR, 2.31, 95 percent CI, 1.82–2.94; p<0.001), although none were of serious severity.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.